# A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA

> **NCT00693186** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 410 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** HBVaxPRO® 5 µg / 0.5 mL
- **BIOLOGICAL:** Engerix B® 10 µg / 0.5 mL

## Key facts

- **NCT ID:** NCT00693186
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-12
- **Final completion:** 2010-03
- **Target enrollment:** 410 (ACTUAL)
- **Last updated:** 2017-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00693186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00693186, "A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00693186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*